نتائج البحث - Marc R. Radke

  • يعرض 1 - 13 نتائج من 13
تنقيح النتائج
  1. 1
    Rare <i>BRIP1</i> Missense Alleles Confer Risk for Ovarian and Breast Cancer

    Rare <i>BRIP1</i> Missense Alleles Confer Risk for Ovarian and Breast Cancer حسب Cassandra L. Moyer, Jennifer Ivanovich, Jessica L. Gillespie, Rachel Doberstein, Marc R. Radke, Marcy E. Richardson, Scott H. Kaufmann, Elizabeth M. Swisher, Paul J. Goodfellow

    منشور في 2019
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  2. 2
    BRCA1 intronic Alu elements drive gene rearrangements and PARP inhibitor resistance

    BRCA1 intronic Alu elements drive gene rearrangements and PARP inhibitor resistance حسب Yifan Wang, Andrea J. Bernhardy, Joseph Nacson, John J. Krais, Yinfei Tan, Émmanuelle Nicolas, Marc R. Radke, Elizabeth Handorf, Alba Llop‐Guevara, Judith Balmañà, Elizabeth M. Swisher, Violeta Serra, Suraj Peri, Neil Johnson

    منشور في 2019
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  3. 3
    Genomic and epigenomic <i>BRCA</i> alterations predict adaptive resistance and response to platinum-based therapy in patients with triple-negative breast and ovarian carcinomas

    Genomic and epigenomic <i>BRCA</i> alterations predict adaptive resistance and response to platinum-based therapy in patients with triple-negative breast and ovarian carcinomas حسب Francesca Menghi, Kalyan Banda, Pooja Kumar, Robert F. Straub, Lacey E. Dobrolecki, Isabel V. Rodriguez, Susan E. Yost, Harshpreet Chandok, Marc R. Radke, George Somlo, Yuan Yuan, Michael T. Lewis, Elizabeth M. Swisher, Edison T. Liu

    منشور في 2022
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  4. 4
    Farletuzumab ecteribulin and MORAb‐109, folate receptor alpha and mesothelin targeting antibody–drug conjugates, show activity in poor prognosis gynaecological cancer models

    Farletuzumab ecteribulin and MORAb‐109, folate receptor alpha and mesothelin targeting antibody–drug conjugates, show activity in poor prognosis gynaecological cancer models حسب Ksenija Nesic, Katherine A. Rybinski, Gayanie Ratnayake, Gwo‐Yaw Ho, Ratana Lim, Marc R. Radke, Chloe Neagle, Elizabeth M. Swisher, Matthew J. Wakefield, Holly E. Barker, Keiji Furuuchi, Clare L. Scott, Cassandra J. Vandenberg

    منشور في 2025
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  5. 5
    Randomized Phase II Study of PARP Inhibitor ABT-888 (Veliparib) with Modified FOLFIRI versus FOLFIRI as Second-line Treatment of Metastatic Pancreatic Cancer: SWOG S1513

    Randomized Phase II Study of PARP Inhibitor ABT-888 (Veliparib) with Modified FOLFIRI versus FOLFIRI as Second-line Treatment of Metastatic Pancreatic Cancer: SWOG S1513 حسب E. Gabriela Chiorean, Katherine A. Guthrie, Philip A. Philip, Elizabeth M. Swisher, Florencia G. Jalikis, Michael J. Pishvaian, Jordan Berlin, Marcus Smith Noel, Jennifer M. Suga, Ignacio Garrido‐Laguna, Dana B. Cardin, Marc R. Radke, Mai Duong, Shay Bellasea, Andrew M. Lowy, Howard S. Höchster

    منشور في 2021
    احصل على النص الكامل احصل على النص الكامل
    Carta
    أضف إلى المفضلة
    محفوظ في:
  6. 6
    <i>BLM</i> overexpression as a predictive biomarker for CHK1 inhibitor response in PARP inhibitor–resistant <i>BRCA</i> -mutant ovarian cancer

    <i>BLM</i> overexpression as a predictive biomarker for CHK1 inhibitor response in PARP inhibitor–resistant <i>BRCA</i> -mutant ovarian cancer حسب Nitasha Gupta, Tzu‐Ting Huang, Jayakumar R. Nair, Daniel An, Grant Zurcher, Erika J. Lampert, Ann McCoy, Ashley Cimino‐Mathews, Elizabeth M. Swisher, Marc R. Radke, Christina M. Lockwood, Jonathan Reichel, Chih-Yuan Chiang, Kelli M. Wilson, Ken Cheng, Darryl Nousome, Jung‐Min Lee

    منشور في 2023
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  7. 7
    The CHK1 inhibitor prexasertib in BRCA wild-type platinum-resistant recurrent high-grade serous ovarian carcinoma: a phase 2 trial

    The CHK1 inhibitor prexasertib in BRCA wild-type platinum-resistant recurrent high-grade serous ovarian carcinoma: a phase 2 trial حسب Elena Giudice, Tzu‐Ting Huang, Jayakumar R. Nair, Grant Zurcher, Ann McCoy, Darryl Nousome, Marc R. Radke, Elizabeth M. Swisher, Stanley Lipkowitz, Kristen R. Ibanez, Duncan Donohue, Tyler Malys, Min-Jung Lee, Bernadette Redd, Elliot Levy, Shraddha Rastogi, N Sato, Jane B. Trepel, Jung‐Min Lee

    منشور في 2024
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  8. 8
    Combination of PARP Inhibitor Olaparib, and PD-L1 Inhibitor Durvalumab, in Recurrent Ovarian Cancer: a Proof-of-Concept Phase II Study

    Combination of PARP Inhibitor Olaparib, and PD-L1 Inhibitor Durvalumab, in Recurrent Ovarian Cancer: a Proof-of-Concept Phase II Study حسب Erika J. Lampert, Alexandra S. Zimmer, Michelle R. Padget, Ashley Cimino‐Mathews, Jayakumar R. Nair, Yingmiao Liu, Elizabeth M. Swisher, James W. Hodge, Andrew B. Nixon, E. Hitt Nichols, Mohammadhadi Bagheri, Elliott Levy, Marc R. Radke, Stanley Lipkowitz, Christina M. Annunziata, Janis M. Taube, Seth M. Steinberg, Jung‐Min Lee

    منشور في 2020
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  9. 9
    Cisplatin with veliparib or placebo in metastatic triple-negative breast cancer and BRCA mutation-associated breast cancer (S1416): a randomised, double-blind, placebo-controlled, phase 2 trial

    Cisplatin with veliparib or placebo in metastatic triple-negative breast cancer and BRCA mutation-associated breast cancer (S1416): a randomised, double-blind, placebo-controlled,... حسب Eve T. Rodler, Priyanka Sharma, William E. Barlow, Julie R. Gralow, Shannon L. Puhalla, Carey K. Anders, Lori J. Goldstein, Debu Tripathy, Ursa Brown‐Glaberman, Thu-Tam Huynh, Christopher S Szyarto, Andrew K. Godwin, Harsh B. Pathak, Elizabeth M. Swisher, Marc R. Radke, Kirsten M. Timms, Danika L. Lew, Jieling Miao, Lajos Pusztai, Daniel F. Hayes, Gabriel N. Hortobágyi

    منشور في 2023
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  10. 10
    Randomized Trial of Olaparib With or Without Cediranib for Metastatic Castration-Resistant Prostate Cancer: The Results From National Cancer Institute 9984

    Randomized Trial of Olaparib With or Without Cediranib for Metastatic Castration-Resistant Prostate Cancer: The Results From National Cancer Institute 9984 حسب Joseph W. Kim, Rana R. McKay, Marc R. Radke, Shilin Zhao, Mary‐Ellen Taplin, Nancy B. Davis, Paul Monk, Leonard J. Appleman, Primo N. Lara, Ulka N. Vaishampayan, Jingsong Zhang, Asit K. Paul, Glenn J. Bubley, Eliezer M. Van Allen, Serhan Ünlü, Ying Huang, Massimo Loda, Geoffrey I. Shapiro, Peter M. Glazer, Patricia LoRusso, S. Percy Ivy, Yu Shyr, Elizabeth M. Swisher, Daniel P. Petrylak

    منشور في 2022
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  11. 11
    <i>BRCA</i> Reversion Mutations in Circulating Tumor DNA Predict Primary and Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma

    <i>BRCA</i> Reversion Mutations in Circulating Tumor DNA Predict Primary and Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma حسب Kevin Lin, Maria I. Harrell, Amit M. Oza, Ana Oaknin, Isabelle Ray‐Coquard, Anna V. Tinker, Elena Helman, Marc R. Radke, Carmen Say, Lan-Thanh Vo, Elaina Mann, Jeffrey D. Isaacson, Lara Maloney, David M. O’Malley, Setsuko K. Chambers, Scott H. Kaufmann, Clare L. Scott, Gottfried E. Konecny, Robert L. Coleman, James Sun, Heidi Giordano, James D. Brenton, Thomas C. Harding, Iain A. McNeish, Elizabeth M. Swisher

    منشور في 2018
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  12. 12
    Acquired <i>RAD51C</i> Promoter Methylation Loss Causes PARP Inhibitor Resistance in High-Grade Serous Ovarian Carcinoma

    Acquired <i>RAD51C</i> Promoter Methylation Loss Causes PARP Inhibitor Resistance in High-Grade Serous Ovarian Carcinoma حسب Ksenija Nesic, Olga Kondrashova, Rachel M. Hurley, Cordelia D. McGehee, Cassandra J. Vandenberg, Gwo‐Yaw Ho, Elizabeth Lieschke, Genevieve Dall, Nirashaa Bound, Kristy Shield‐Artin, Marc R. Radke, Ashan Musafer, Zi Qing Chai, Mohammad Reza Eftekhariyan Ghamsari, Maria I. Harrell, Damien Kee, Inger Olesen, Orla McNally, Nadia Traficante, Australian Ovarian Cancer Study, Anna deFazio, David D.L. Bowtell, Elizabeth M. Swisher, S. John Weroha, Kátia Nones, Nicola Waddell, Scott H. Kaufmann, Alexander Dobrovic, Matthew J. Wakefield, Clare L. Scott

    منشور في 2021
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  13. 13
    BRCA1 secondary splice-site mutations drive exon-skipping and PARP inhibitor resistance

    BRCA1 secondary splice-site mutations drive exon-skipping and PARP inhibitor resistance حسب Ksenija Nešić, John J. Krais, Yifan Wang, Cassandra J. Vandenberg, Pooja Patel, Kathy Q. Cai, Tanya T. Kwan, Elizabeth Lieschke, Gwo‐Yaw Ho, Holly E. Barker, Justin Bedő, Silvia Casadei, Andrew Farrell, Marc R. Radke, Kristy Shield‐Artin, Jocelyn Sietsma Penington, Franziska Geissler, Elizabeth L. Kyran, Robert Betsch, Lijun Xu, Fan Zhang, Alexander Dobrovic, Inger Olesen, Rebecca Kristeleit, Amit M. Oza, Iain A. McNeish, Gayanie Ratnayake, Nadia Traficante, Georgia Chenevix‐Trench, A Green, Penelope M. Webb, Dorota M. Gertig, Sián Fereday, Suzanne Moore, Jillian A. Hung, K.R. Harrap, T. Sadkowsky, Nirmala Pandeya, M. Malt, A. Mellon, R. Paul Robertson, T. Vanden Bergh, Milissa U. Jones, P. Mackenzie, J. Maidens, K. Nattress, Yoke-Eng Chiew, Annie Stenlake, Harold C. Sullivan, Brian M. Alexander, P. Ashover, Stephen M. Brown, T. Corrish, L. Green, L. M. Jackman, Kaltin Ferguson, Karla Martin, A. Martyn, B. Ranieri, J. White, V. Jayde, Pam Mamers, Leanne Bowes, Laura Galletta, Daniel A. Giles, Joy Hendley, Thomas Schmidt, H. Shirley, C. Ball, Christian D. Young, S. Viduka, Hang Tran, Sanela Bilic, Lydia Glavinas, Julia Brooks, R. Stuart‐Harris, Fred Kirsten, J Rutovitz, P. Clingan, Akisha Glasgow, Anthony Proietto, Stephen Braye, Geoffrey Otton, Jenny Shannon, Tony Bonaventura, James Stewart, Stephen Begbie, Michael Friedlander, Debra Bell, Sally Baron‐Hay, A. Ferrier, G. Gard, David Nevell, Nick Pavlakis, Susan Valmadre, Bruce W. Young, C. Camaris, R. Crouch, L. Edwards, Neville F. Hacker

    منشور في 2024
    احصل على النص الكامل
    Carta
    أضف إلى المفضلة
    محفوظ في:

أدوات البحث: